The National Cancer Institute (NCI) awarded a $349,808 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Oncurie Inc. to continue development of their novel, targeted radiopharmaceutical platform for imaging and potential future therapy of ovarian cancer. The platform leverages a folate receptor-binding moiety and Oncurie's proprietary radionuclide-binding technology to specifically target and deliver radionuclides to ovarian tumors. During this Phase I STTR project, Oncurie will refine the compound's molecular structure and formulation, confirm its targeting properties in vitro, and evaluate its performance in a patient-derived xenograft model. Pending successful completion, Oncurie plans to advance the compound through further safety, toxicology, and efficacy testing required for an Investigational New Drug (IND) application to enable clinical studies.
Generated 1/28/25, 10:02 AM